NewTimeSpace News:As of 13:08 on February 10, 2026, the CSI Biomedical Index (930726) surged 1.21%. Among its constituent stocks, Rongchang Bio rose 5.65%, BeiGene climbed 3.64%, Zejing Pharmaceutical advanced 3.23%, with WuXi AppTec, Dizhe Pharmaceutical and other stocks following the upward trend. The Guotai CSI BIOMEDICINE ETF (512290) rose 1.19% to close at RMB 1.02. Over a longer time frame, as of February 9, 2026, the ETF had a cumulative gain of 2.22% in the past week. (The stocks listed above are merely constituent stocks of the index and do not constitute specific investment recommendations.)

In terms of liquidity, the Guotai CSI BIOMEDICINE ETF recorded an intraday turnover rate of 1.93% with a trading volume of RMB 73.5332 million. As of February 9, the ETF's average daily trading volume in the past month reached RMB 104 million.

In terms of scale, the latest size of the Guotai CSI BIOMEDICINE ETF stood at RMB 3.771 billion, hitting a six-month high. (Data source: Wind)

In terms of share count, the latest share count of the Guotai CSI BIOMEDICINE ETF reached 3.732 billion shares, a six-month high. (Data source: Wind)

In terms of net capital inflows, the Guotai CSI BIOMEDICINE ETF has registered consecutive net capital inflows over the recent three days, with a maximum single-day net inflow of RMB 6.0555 million, a total capital inflow of RMB 12.1097 million and an average daily net inflow of RMB 4.0366 million. (Data source: Wind)

Data shows that leveraged capital has been continuously building positions in the ETF. The latest margin purchase amount of the Guotai CSI BIOMEDICINE ETF reached RMB 7.9344 million, with the latest margin trading balance standing at RMB 158 million. (Data source: Wind)

As of February 9, the net asset value of the Guotai CSI BIOMEDICINE ETF had risen 10.61% in the past year. In terms of profitability, as of February 9, 2026, since its establishment, the ETF has achieved a maximum monthly return of 23.26%, a record of 8 consecutive months of gains with a cumulative increase of 109.28%, and an average monthly return of 6.56% in upward months. As of February 9, 2026, the ETF had an annualized excess return of 2.59% over the benchmark since its inception.

In terms of drawdown, as of February 9, 2026, the ETF had a relative benchmark drawdown of 0.05% since the start of the year.

Regarding fees, the Guotai CSI BIOMEDICINE ETF has a management fee rate of 0.50% and a custodian fee rate of 0.10%.

In terms of tracking accuracy, as of February 9, 2026, the ETF had a tracking error of 0.007% since the beginning of the year.

The Guotai CSI BIOMEDICINE ETF closely tracks the CSI Biomedical Index, which selects listed company securities that provide products and services such as cellular medicine, gene sequencing, blood products, biotech drugs, vaccines and in vitro diagnostics as index samples, so as to reflect the overall performance of listed biomedical company securities.

Data shows that as of January 30, 2026, the top 10 weighted stocks of the CSI Biomedical Index (930726) were WuXi AppTec, Hengrui Medicine, Mindray Medical, Shanghai RAAS Blood Products, BeiGene, Changchun High-tech, Ailisheng Pharmaceutical, Gan & Lee Pharmaceuticals, New Industries Biomedical Engineering and Zhifei Biological Products, accounting for a total of 67.63% of the index's weight. (The stocks listed above are merely constituent stocks of the index and do not constitute specific investment recommendations.)

Huafu Securities stated that the global biomedical industry is showing a "cautiously optimistic" trend in 2026. To cope with the upcoming patent cliff, enterprises are accelerating their M&A layout, with the M&A volume in the biotech field reaching 36 billion US dollars in October-November 2025 alone.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.